Evaluate value of serum PLOD3 and CYFRA21-1 on the efficacy of three-dimensional brachytherapy in patients with lung metastases
10.3969/j.issn.1006-5725.2025.01.020
- VernacularTitle:血清PLOD、CYFRA21-1水平对肺转移瘤患者三维近距离插植放疗疗效的评估价值
- Author:
Tingting HU
1
;
Hongling LU
1
;
Xiaoming YIN
1
;
Qian LIU
1
;
Wei GUO
1
;
Yunchuan SUN
1
Author Information
1. 河北省沧州中西医结合医院放化疗一科(河北 沧州 061000)
- Publication Type:Journal Article
- Keywords:
procollagen-lysine,2-Oxoglutarate 5-Dioxygenase 3;
cytokeratin 19 fragment antigen 21-1;
pulmonary metastases;
three-dimensional brachytherapy;
treatment effectiveness
- From:
The Journal of Practical Medicine
2025;41(1):120-125
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the prognostic value of serum lysine hydroxylase 3(PLOD3)and cytokeratin 19 fragment(CYFRA21-1)in predicting the efficacy of three-dimensional brachytherapy in patients with pulmonary metastases.Methods A total of 102 patients with lung metastases who underwent three-dimensional brachytherapy at our hospital were selected as the lung metastasis group from August 2021 to August 2023.During the same period,a control group consisting of 60 healthy individuals who underwent physical examinations was selected.The lung metastasis group was further divided into an effective group(n=66)and an ineffective group(n=36)based on therapeutic outcomes.Enzyme-linked immunosorbent assay was employed to measure the levels of serum PLOD3 and CYFRA21-1.Multiple logistic regression analysis was conducted to identify factors influencing the efficacy of three-dimensional brachytherapy in the lung metastasis group.Receiver operating characteristic(ROC)curves were used to assess the predictive value of serum PLOD3 and CYFRA21-1 for treatment efficacy.Results The levels of serum PLOD3 and CYFRA21-1 in the case group were(34.47±6.17)μg/L,(27.85±5.14)μg/L,respectively,which exhibited significantly higher values compared to those observed in the control group(7.26±2.21)μg/L,(9.31±2.46)μg/L(P<0.05).A positive correlation was found between serum PLOD3 and CYFRA21-1 in the Lung metastasis group(r=0.667,P=0.000).Logistic regression analysis revealed that multiple metastatic lesions along with elevated serum levels of PLOD3 and CYFRA21-1 were identified as risk factors for the efficacy of three-dimensional brachytherapy in patients with lung metastases(P<0.05).Furthermore,when combined with three-dimensional brachytherapy,the area under the curve(AUC)for serum PLOD3 and CYFRA21-1 was calcu-lated as 0.868,demonstrating a superior performance compared to individual measurements of either serum PLOD3 alone(AUC=0.815)or CYFRA21-1 alone(P<0.05).Conclusions The levels of serum PLOD3 and CYFRA21-1 are elevated in patients with lung metastases,exhibiting a significant correlation with the efficacy of three-dimensional brachytherapy.The combined utilization of these two biomarkers demonstrates a robust predictive value for treatment efficacy in patients suffering from lung metastases.
